Associated Papers
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
Nakauma-González JA et al.
Cell Genomics, 2024
38552621 (PubMed )
Supplement: mmc7.xlsx › S6.Driver_ApoHM
Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected response.
Daugan C et al.
Therapeutic Advances in Medical Oncology, 2024
Gene mutations in sporadic lymphangioleiomyomatosis and genotype-phenotype correlation analysis.
Huang J et al.
Bmc Pulmonary Medicine, 2022
36117164 (PubMed )
Supplement: 12890_2022_2154_MOESM4_ESM.xlsx › sheet1
Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.
Szymansky A et al.
Journal of Personalized Medicine, 2021
34442335 (PubMed )
Supplement: jpm-11-00691-s001.zip › S15-SNVs_routine_cohort.xlsx › SNVs_Bigcohort
Multiregional Sequencing of IDH-WT Glioblastoma Reveals High Genetic Heterogeneity and a Dynamic Evolutionary History.
Franceschi S et al.
Cancers, 2021
33922652 (PubMed )
Supplement: cancers-13-02044-s001.zip › Supplementary_Table_S3.xlsx › Supplementary_Table_S3
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA et al.
Acta Neuropathologica Communications, 2020
33087175 (PubMed )
Supplement: 40478_2020_1040_MOESM1_ESM.xlsx › Sheet1
Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia.
Wu N et al.
Journal of Cellular and Molecular Medicine, 2020
32277576 (PubMed )
Supplement: JCMM-24-4931-s011.xlsx › Sheet1
Select a paper to view details